Start Your Search
P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
P1.01-056 - A Prospective Audit on Toxicity for Platinum-Based Chemotherapy in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): A West of Scotland Analysis (ID 2433)
09:30 - 17:00 | Author(s): J. McPhelim
The current standard of care for patients with Stage IIIB/IV NSCLC with no activating Epidermal Growth Factor Receptor (EGFR) mutations recommends platinum (carboplatin or cisplatin) doublet chemotherapy in patients who are performance status 0-2. Although a number of options are available, evidence from Phase 3 Randomised Controlled Trials have previously shown no differences in survival outcomes in non-pemetrexed based regimens. We set out to prospectively audit toxicity and efficacy of four commonly offered platinum-based doublets in the West of Scotland with a view to making comparative conclusions from our data.
Patients undergoing first line palliative chemotherapy with a platinum doublet in two lung cancer clinics in the West of Scotland (Glasgow and Lanarkshire) between July 2014 and April 2015 were included. Baseline demographics were obtained and entered into a common database. On each attendance for chemotherapy pre-assessment, toxicity data was recorded using CTC version 4.0 and prospectively entered into the database. Requirements for admission to hospital and the need for blood and platelet transfusions were also recorded.
To date 54 patients have been included. The median number of chemotherapy cycles was 2.7(150). 55% (30) of patients were male and 45% (24) female, with the majority sub-type being adenocarcinomas. The most commonly prescribed agent with platinum was pemetrexed (52%) followed by gemcitabine (24%) and vinorelbine (22%). The use of paclitaxel was lower than anticipated (2%). Toxicity data is available for all 54 patients (see table 1). Survival outcomes will be reported subsequently along with ongoing collated data on toxicity in additional patients in this prospective audit. Table 1. Figure 1
First line treatment of advanced NSCLC with platinum doublets in the West of Scotland is generally well tolerated. Toxicities exceeding Grade 2 were uncommon with any of the 4 platinum doublets. However, hospital admission was more likely in those receiving pemetrexed or vinorelbine doublets. The need for blood transfusion was more common in doublets containing pemetrexed or gemcitabine.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.